Home Breast Cancer Hologic Looks to Expand Profile in Breast Cancer Testing With Biotheranostics Acquisition

Hologic Looks to Expand Profile in Breast Cancer Testing With Biotheranostics Acquisition

62
0

NEW YORK – Already an established presence in the breast cancer testing space, Hologic’s planned acquisition of Biotheranostics provides an opportunity to further expand its footprint in that market, according to company executives.

Last week, Hologic announced the deal to acquire molecular diagnostics firm Biotheranostics for approximately $230 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

https://www.genomeweb.com/business-news/hologic-looks-expand-profile-breast-cancer-testing-biotheranostics-acquisition

This site uses Akismet to reduce spam. Learn how your comment data is processed.